Global /Japan /Healthcare /Drug Manufacturers - General /4594

BrightPath Biotherapeutics Co., Ltd.

4594

• TSE: 4594 • Delayed

55JPY -1.8%

0.3430 USD

As of 10 June 2026, BrightPath Biotherapeutics Co., Ltd. has a market cap of $46.35M USD, ranking #31106 globally and #2916 in Japan. It ranks #2806 in the Healthcare sector, and #978 in the Drug Manufacturers - General industry.

Global Rank

31106

Country Rank

2916

Sector Rank

2806

Industry Rank

978

Key Stats

Market Cap

$46.35MUSD

7.43B JPY

Enterprise Value

$40.46MUSD

6.49B JPY

Revenue (TTM)

$6.72KUSD

1.08M JPY

Net Income (TTM)

-$8.05MUSD

-1.29B JPY

PS Ratio

6900.9

PB Ratio

6.7

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Kenichi Nagai open_in_new

Employees

Founded

2003

Website

brightpathbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.8%	-11%	-29%	-13%	-8.3%	15%	41%	-62%	-71%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4594 ブライトパス・バイオ株式会社 ISIN: JP3274140007 Shares Out.: Shares Outstanding: 138.891M¹ Shares Float: 135.732M² TV: TradingView: TSE: 4594 SA: Stock Analysis: TYO: 4594 YF: Yahoo Finance: 4594.T GF: Google Finance: TYO: 4594 BA: Barron's: 4594 MS: Morningstar: XTKS: 4594	55 JPY	TV: TradingView: TSE: 4594 SA: Stock Analysis: TYO: 4594 YF: Yahoo Finance: 4594.T GF: Google Finance: TYO: 4594 BA: Barron's: 4594 MS: Morningstar: XTKS: 4594

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.49B 13.07T JPY 176K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.11B 8.36T JPY 112K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.76B 5.9T JPY 79K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.31B 4.86T JPY 65K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.76B 4.13T JPY 55K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.88B 2.71T JPY 36K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 778K%	97.4	United States
Roche Holding AG SIX: RO	$321.17B 256.25B CHF 693K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$287.57B 215.59B GBP 620K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.35B 218.9B CHF 592K%	20.5	Switzerland

chevron_leftBack